Anghelescu Doralina L, Faughnan Lane G, Baker Justin N, Yang Jie, Kane Javier R
Division of Anesthesiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Paediatr Anaesth. 2010 Dec;20(12):1070-7. doi: 10.1111/j.1460-9592.2010.03449.x.
Clinicians may avoid continuous pain blocks in pediatric cancer patients at the end of life for fear of complications or of interfering with the desired location of death.
To examine the impact of epidural or peripheral nerve catheters on pain control in children and young adults with cancer within the last 3 months of life.
We retrospectively reviewed the medical records to assess pain scores, systemic opioid requirements, and impact on death at the preferred location.
Ten patients (4.4-21.3 years of age), nine with solid tumors, one with lymphoma, had 14 devices (11 epidural, 3 peripheral nerve catheters) for a range of 3-81 days. Twelve of 13 catheters provided improvement by at least one of three criteria: improved mean pain scores at 24 h (8 of 13) and decreased opioid requirement at 24 h in nine cases and at day 5 in nine cases. Eight patients died in their preferred setting. Six patients had catheters (five epidural, one peripheral) until death, including two who died at home. In some cases, typical contraindications for indwelling catheters (spinal metastasis, vertebral fracture, thrombocytopenia, fever) were superseded by palliative care needs. We found no bleeding, infectious, or neurological complications.
Our findings suggest that continuous catheter-delivered pain blockade at the end of life contributes to analgesia, moderates opioid requirements, and usually does not preclude death at the preferred location.
临床医生可能会避免在儿科癌症患者生命末期进行持续疼痛阻滞,因为担心出现并发症或干扰预期的死亡地点。
研究硬膜外或外周神经导管对癌症患儿及青年患者生命最后3个月疼痛控制的影响。
我们回顾性分析了病历,以评估疼痛评分、全身性阿片类药物需求以及对在首选地点死亡的影响。
10名患者(年龄4.4 - 21.3岁),9名患有实体瘤,1名患有淋巴瘤,共使用了14根导管(11根硬膜外导管,3根外周神经导管),使用时间为3 - 81天。13根导管中有12根至少在以下三个标准中的一项上有所改善:24小时平均疼痛评分改善(13根中有8根),9例患者24小时阿片类药物需求量减少,9例患者在第5天阿片类药物需求量减少。8名患者在其首选地点死亡。6名患者直至死亡时仍保留导管(5根硬膜外导管,1根外周导管),其中2名在家中死亡。在某些情况下,留置导管的典型禁忌证(脊髓转移、椎体骨折、血小板减少、发热)被姑息治疗需求所取代。我们未发现出血、感染或神经并发症。
我们的研究结果表明,在生命末期通过导管进行持续疼痛阻滞有助于镇痛,降低阿片类药物需求,并且通常不排除在首选地点死亡。